Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Study shows ritonavir-boosted nirmatrelvir remains effective against new omicron variants in the U.S

Study shows ritonavir-boosted nirmatrelvir remains effective against new omicron variants in the U.S

Paxlovid enhances treatment options for COVID-19 patients

Paxlovid enhances treatment options for COVID-19 patients

Paxlovid treatment in 20% of COVID-19 patients could avert 850,000 hospitalizations, save up to $170 billion

Paxlovid treatment in 20% of COVID-19 patients could avert 850,000 hospitalizations, save up to $170 billion

Nirmatrelvir treatment shows no link to reduced long-COVID risk, study reveals

Nirmatrelvir treatment shows no link to reduced long-COVID risk, study reveals

Paxlovid does not reduce long COVID risk in vaccinated individuals, study finds

Paxlovid does not reduce long COVID risk in vaccinated individuals, study finds

Exploring the global health challenge of hepatitis D

Exploring the global health challenge of hepatitis D

Research shows how HIV drug could stop many coronavirus diseases

Research shows how HIV drug could stop many coronavirus diseases

Exploring the dual role of nirmatrelvir and bisphosphonates in COVID-19 treatment and immunity

Exploring the dual role of nirmatrelvir and bisphosphonates in COVID-19 treatment and immunity

One in five patients on Nirmatrelvir–Ritonavir experience virologic rebound, new observational study reveals

One in five patients on Nirmatrelvir–Ritonavir experience virologic rebound, new observational study reveals

Study observes virologic rebound in 20% of COVID-19 patients treated with nirmatrelvir-ritonavir

Study observes virologic rebound in 20% of COVID-19 patients treated with nirmatrelvir-ritonavir

One in five individuals taking nirmatrelvir-ritonavir therapy found to experience rebound COVID

One in five individuals taking nirmatrelvir-ritonavir therapy found to experience rebound COVID

WHO experts update guidance on COVID-19 treatments

WHO experts update guidance on COVID-19 treatments

Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19

Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19

Paxlovid treatment provides protection against COVID-19 for both mother and child

Paxlovid treatment provides protection against COVID-19 for both mother and child

Nirmatrelvir and ritonavir combo cuts COVID-19 risks for high-vulnerability groups

Nirmatrelvir and ritonavir combo cuts COVID-19 risks for high-vulnerability groups

NIH launches and opens enrollment for phase 2 clinical trials to evaluate long COVID treatments

NIH launches and opens enrollment for phase 2 clinical trials to evaluate long COVID treatments

Oral antivirals Molnupiravir and Nirmatrelvir-Ritonavir lower COVID-19 risks in type 2 diabetes patients

Oral antivirals Molnupiravir and Nirmatrelvir-Ritonavir lower COVID-19 risks in type 2 diabetes patients

Nanoparticles take aim at COVID-19 with lysosome-targeted delivery

Nanoparticles take aim at COVID-19 with lysosome-targeted delivery

Nirmatrelvir/ritonavir reduces the risk of COVID-19-associated hospitalization

Nirmatrelvir/ritonavir reduces the risk of COVID-19-associated hospitalization

Molnupiravir treatment reduces risk of long COVID in high risk patients

Molnupiravir treatment reduces risk of long COVID in high risk patients